These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 7836510)

  • 1. Long-term medical therapy for leiomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin 'add-back' for 2 years.
    Friedman AJ; Daly M; Juneau-Norcross M; Gleason R; Rein MS; LeBoff M
    Hum Reprod; 1994 Sep; 9(9):1618-25. PubMed ID: 7836510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin "add-back" regimens for women with leiomyomata uteri.
    Friedman AJ; Daly M; Juneau-Norcross M; Rein MS; Fine C; Gleason R; Leboff M
    J Clin Endocrinol Metab; 1993 Jun; 76(6):1439-45. PubMed ID: 8501148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estriol add-back therapy in the long-acting gonadotropin-releasing hormone agonist treatment of uterine leiomyomata.
    Nakayama H; Yano T; Sagara Y; Kikuchi A; Ando K; Wang Y; Watanabe M; Matsumi H; Osuga Y; Momoeda M; Taketani Y
    Gynecol Endocrinol; 1999 Dec; 13(6):382-9. PubMed ID: 10685331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group.
    Hornstein MD; Surrey ES; Weisberg GW; Casino LA
    Obstet Gynecol; 1998 Jan; 91(1):16-24. PubMed ID: 9464714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term gonadotrophin-releasing hormone agonist therapy: the evolving issue of steroidal 'add-back' paradigms.
    Adashi EY
    Hum Reprod; 1994 Jul; 9(7):1380-97. PubMed ID: 7962453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
    Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F
    Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Adherence, Persistence, and Surgery Among Endometriosis Patients Treated with Leuprolide Acetate Plus Norethindrone Acetate Add-Back Therapy.
    Soliman AM; Bonafede M; Farr AM; Castelli-Haley J; Winkel C
    J Manag Care Spec Pharm; 2016 May; 22(5):573-87. PubMed ID: 27123918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intermittent leuprolide acetate for the nonsurgical management of women with leiomyomata uteri.
    Scialli AR; Levi AJ
    Fertil Steril; 2000 Sep; 74(3):540-6. PubMed ID: 10973652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study. The Leuprolide Study Group.
    Friedman AJ; Hoffman DI; Comite F; Browneller RW; Miller JD
    Obstet Gynecol; 1991 May; 77(5):720-5. PubMed ID: 1901638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas.
    Simon JA; Al-Hendy A; Archer DF; Barnhart KT; Bradley LD; Carr BR; Dayspring T; Feinberg EC; Gillispie V; Hurtado S; Kim J; Liu R; Owens CD; Muneyyirci-Delale O; Wang A; Watts NB; Schlaff WD
    Obstet Gynecol; 2020 Jun; 135(6):1313-1326. PubMed ID: 32459423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of ipriflavone in preventing adverse effects of leuprolide.
    Somekawa Y; Chiguchi M; Ishibashi T; Wakana K; Aso T
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3202-6. PubMed ID: 11443189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Add-back" estrogen reverses cognitive deficits induced by a gonadotropin-releasing hormone agonist in women with leiomyomata uteri.
    Sherwin BB; Tulandi T
    J Clin Endocrinol Metab; 1996 Jul; 81(7):2545-9. PubMed ID: 8675575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of a low-dose leuprolide acetate depot in the treatment of uterine leiomyomata in Japanese women.
    Watanabe Y; Nakamura G; Matsuguchi H; Nozaki M; Sano M; Nakano H
    Fertil Steril; 1992 Jul; 58(1):66-71. PubMed ID: 1624025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short term treatment with leuprolide acetate is a successful adjunct to surgical therapy of leiomyomas of the uterus.
    Coddington CC; Brzyski R; Hansen KA; Corley DR; McIntyre-Seltman K; Jones HW
    Surg Gynecol Obstet; 1992 Jul; 175(1):57-63. PubMed ID: 1621201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome.
    Mezrow G; Shoupe D; Spicer D; Lobo R; Leung B; Pike M
    Fertil Steril; 1994 Nov; 62(5):932-7. PubMed ID: 7926137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged gonadotropin-releasing hormone agonist treatment of symptomatic endometriosis: the role of cyclic sodium etidronate and low-dose norethindrone "add-back" therapy.
    Surrey ES; Voigt B; Fournet N; Judd HL
    Fertil Steril; 1995 Apr; 63(4):747-55. PubMed ID: 7890057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of steroid add-back therapy on the proliferative activity of uterine leiomyoma cells under gonadotropin-releasing hormone agonist therapy.
    Mizutani T; Sugihara A; Honma H; Komura H; Nakamuro K; Terada N
    Gynecol Endocrinol; 2005 Feb; 20(2):80-3. PubMed ID: 15823826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effects of add-back therapy with various natural oestrogens on bone metabolism in rats administered a long-acting gonadotrophin-releasing hormone agonist.
    Wang Y; Yano T; Kikuchi A; Yano N; Matsumi H; Ando K; Kasai Y; Watanabe M; Okagaki R; Osuga Y; Taketani Y
    J Endocrinol; 2000 May; 165(2):467-73. PubMed ID: 10810310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of leiomyomata uteri with short-term leuprolide followed by leuprolide plus estrogen-progestin hormone replacement therapy for 2 years: a pilot study.
    Friedman AJ
    Fertil Steril; 1989 Mar; 51(3):526-8. PubMed ID: 2537769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up.
    Surrey ES; Hornstein MD
    Obstet Gynecol; 2002 May; 99(5 Pt 1):709-19. PubMed ID: 11978277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.